Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis

Hospital Clinic of Barcelona255 enrolled

Overview

The study compares the adherence of 240 HIV-negative subjects randomly assigned to 2 different antiretroviral therapies for 28 days after accidental exposure to HIV.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

255

Conditions

HIV Infections

Interventions

Combivir+KaletraDRUG

Combivir+ReyatazDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \> 18 * HIV exposure requiring prophylaxis under current guidelines Exclusion Criteria: * Pregnancy * Suspected drug resistance in source case * Contraindications to the study drugs

Locations (7)

Hospital Universitari Germans Trias i Pujol

Badalona, Barcelona, Spain

Hospital del Mar

Barcelona, Barcelona, Spain

Hospital de Sant Pau

Barcelona, Barcelona, Spain

Hospital Vall d'Hebron

Barcelona, Barcelona, Spain

Outcomes

Primary Outcomes

Proportions of patients completing 28-day antiretroviral treatment (ARVT)

Secondary Outcomes

Proportion of HIV-seropositive at 6 months

Incidence of adverse effects (clinical and laboratory) during ARVT

Adherence to ARVT, time to adherence loss.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.